Abstract 2053P
Background
In recent decades, the home care initiative has expanded in the health system, mainly linked to hospitals. The mismatch between available financial resources and advances related to cancer therapy requires projects to improve cost minimization processes.
Methods
The variables collected for each sector were described through monthly totals and averages per year. To verify the existence of an association between expenses with material, medication and chemotherapy and the cost avoided with monthly dehospitalization, Pearson's correlation coefficients and their respective p-values were calculated. Spending on medication and total spending on material, medication and chemotherapy were related to the amount avoided using linear regression models, in order to estimate the effect of increased spending on medication on avoided costs. The same procedure was performed to estimate the effect of increased costs on bed turnover, using linear regressions, and on the number of days of hospitalization avoided per month, using Poisson regression.
Results
Pearson's coefficients confirm a relationship, with a positive sign, between expenses and avoided costs with early dehospitalization, showing a perfect positive relationship between the variables, with a statistically significant p-value. Effect of expenses on total costs with hospitalization avoided on General Hospitalization, Coefficients - Amount spent on medication:100.36; 95% CI (14.26, 186.45); p-value= 0.02. By the linear model, the total avoided cost with discharges was $795,204.52 in the three-year period from 2020 to 2022, for a total of 3,722 avoided hospitalization days and an average cost avoided with discharges of $70,146.06. Effect of expenses on the days of hospitalization avoided (Poisson regression) was statistically significant in all variables (p-value<0.001).
Conclusions
All tests - Pearson Correlation coefficients, Poisson regression, and Generalized Linear Model (p<0.05) confirmed the hypothesis that the discharge managing with outpatient drug release has a significant effect on the final cost avoided with cancer hospitalization.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06